Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
In-depth Wall Street fundamental and technical research. Get past all the hype and go strait to the numbers with every type of valuation measure imaginable. Including individual stock, industry, sector, country and exchange analysis, as well as competitor and benchmark comparisons. Access our proprietary lists and value rating system, all for free at ExtremeValueStocks.com - Sign up for an elite membership and get no ads, more detailed list views and our Extreme Comparison Tool. Seeking Alpha members please enjoy a complimentary two week trial:
Mr. Becker has more than 15-years of experience as a serial entrepreneur, C-level industry executive, drug developer, Wall Street securities analyst and registered financial advisor. He is also an online communications pioneer, popular blogger, and a sought-after speaker at industry events.
Before establishing MD Becker Partners LLC (www.mdbpartners.com) in 2008, he served as president, chief executive officer, and member of the Board of Directors for several publicly-traded biotechnology companies including commercial-stage Cytogen Corporation (acquired by EUSA Pharma) and development-stage VioQuest Pharmaceuticals, Inc.
While at Cytogen, Mr. Becker held positions of increasing responsibility, including Vice President of Business Development, Industry Relations, Investor Relations and Chief Executive Officer of AxCell Biosciences, a subsidiary of Cytogen focused on signal transduction pathways. During his tenure at Cytogen, Mr. Becker raised in excess of $130 million in new capital through both public offerings and private placements and in-licensed Caphosol(c), a topical oral agent and prescription medical device for the treatment of oral mucositis and xerostomia.
Prior to joining Cytogen, Mr. Becker was with Wayne Hummer Investments LLC, a Chicago-based regional brokerage firm, where he held senior positions as a biotechnology securities analyst, financial advisor and portfolio manager. He was also the founder and Executive Editor of Beck on Biotech, a monthly biotechnology investment newsletter published from July 1998 through March 2001. Mr. Becker was previously with Kidder, Peabody & Co., Gruntal & Co., L.L.C., and Kemper Securities. He has previously held the following financial licenses: Series 7 (Registered Representative), Series 16 (Securities Analyst), Series 63 (Uniform Securities Agent) and Series 65 (Registered Investment Advisor).
Mr. Becker plays an active leadership role as an advocate for the biotechnology industry. He is past Chairman and member of the board of trustees with BioNJ, which is New Jersey's trade association for biotechnology companies, and is currently a member of BioNJ, Pennsylvania Bio, the New Jersey Technology Council (NJTC), and the Pharmaceutical Consulting Consortium, Inc. (PCCI). Mr. Becker placed as a biotechnology/life sciences finalist for the Ernst & Young Entrepreneur of the Year award in both 2004 and 2005 and was listed in BusinessWeek's "CEO's 40 and Under" article in December 2006. He attended DePaul University in Chicago, Illinois.
MD Becker Partners newsletter site can be found at: http://lifesciencedigest.com
Justin M. Hall is an extremely accomplished independent financial analyst with more than a decade of experience in the financial markets. He consistently provides expertise to a variety of financial clients and is known for his successful market predictions. Between 2010 and 2014 Justin made 239 specific market recommendations via his online subscription service with an 80% accuracy rate. He has produced enduring results for a variety of clients including those who trade stocks, invest their own money, desire personal wealth management, and institutional investors. But more than an analyst, Justin is a person who influences and persuades, whose judgement is well respected and highly trusted, and whose opinion is sought by those searching for financial and investment advice.
Justin received his undergraduate degree from Indiana State University and attended law school at Indiana University. His desire to serve the financial and investment needs of individual clients led him to start Rx Investors.com, an online subscription service that connected individual investors with his expert analysis. Subscribers from all over the world utilized Justin’s advice to generate market income and grow their individual portfolios. Many of these subscribers and clients continued to seek Justin’s analysis and advice for many years, appreciating his unique perspective on the financial industry.
A variety of financial outlets have recognized Justin’s expertise and highlighted his work including the Orange County Business Journal, Seeking Alpha, and Zack’s Investment Research. These industry connections have allowed Justin to lend his expert advice to others and expand his influence.